Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate.

  title={Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate.},
  author={Decio Armanini and Cristina Fiore and Donatella Pellati},
  volume={50 4},
To the Editor: Primary aldosteronism (PA) is the most common form of secondary hypertension. The prevalence of PA is raised from 1% to 3% to 10% to 15% because of the introduction of the upright plasma aldosterone/plasma renin activity ratio (APR) as screening procedure.1 The pathogenesis of idiopathic PA (IPA), which accounts for 50% of the cases of PA, is still not clear, and several factors have been involved, such as hypersensitivity to angiotensin II or to other stimulating factors or… Expand
Some considerations about evolution of idiopathic primary aldosteronism
It is not excluded that aldosterone receptor blockers could prevent the onset of idiopathic hyperaldosteronism and its complications in patients with hypertension without primary hyperaldeeronism. Expand
Enigma of the Origin of Primary Aldosteronism.
The study reports differences between ELISA measurement of the antibodies and the functional, cell-based assay and an association between increased levels of agonistic AT1AR-Ab and aldosterone to renin ratio in a large cohort of patients with BAH, but these characteristics were also evident in the other groups. Expand
Some Considerations About Primary Aldosteronism and Its Follow‐Up
The conclusion of this study was that prolonged treatment with ARBs is considered the gold standard for the diagnosis of PA, and Adrenal vein catheterization (AVC) should be interpreted with caution in patients without clear evidence of unilateral adenoma. Expand
Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
It is demonstrated that SP not only antagonizes the MR, but also decreases aldosterone synthetic activity, which may produce remission in some patients with unilateral PA. Expand
Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion.
It is suggested that mineralocorticoid hyperfunction in patients with PA after medical treatment may decline spontaneously, and higher potassium concentration and duration of treatment seem to increase the probability of this event. Expand
Syndromes that Mimic an Excess of Mineralocorticoids
Pseudohyperaldosteronism is characterized by a clinical picture of hyperaldosteronism with suppression of renin and aldosterone. It can be due to endogenous or exogenous substances that mimic theExpand
Pharmacological treatment of aldosterone excess.
Clinical research will provide the answers as to which drugs and strategies to treat high-aldosterone states are the most effective, calling for specific anti-ald testosterone drugs. Expand
Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.
Two studies have compared the effects of surgery and mineralocorticoid antagonists either on BP, on serum potassium levels, or on the incidence of cardiovascular and renal outcomes in patients with primary aldosteronism with or without an APA; these studies found no difference between the two therapeutic options. Expand
MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited.
The recent developments and current approaches to the medical management of the syndrome of primary aldosteronism are presented. Expand
Spironolactone in the treatment of polycystic ovary syndrome
SP is the only antiandrogen approved for hirsutism in the United States and has been in use for this reason for more than three decades with close to 300 entries in Pub Med. Expand


Idiopathic primary hyperaldosteronism: Normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate
It is concluded that long-term therapy with the aldosterone-receptor blocker, potassium canrenoate, can normalize the aaldo/PRA ratio in many cases of idiopathic primary hyperaldosteronism after one-month withdrawal of the drug. Expand
Primary aldosteronism: diagnostic and treatment strategies
Optimal treatment for aldosterone-producing adenoma or unilateral hyperplasia is unilateral laparoscopic adrenalectomy and the idiopathic bilateralhyperplasia and glucocorticoid-remediable aldosteronism subtypes should be treated pharmacologically. Expand
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure. Expand
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. Expand
Changes in the Renin-Angiotensin-Aldosterone Axis in Later Life
It is shown that reductions in blood pressure, induced by short or long term treatment with angiotensin converting enzyme (ACE) inhibitors, were more pronounced in old than young hypertensive patients, and the genotype deletion/deletion of this gene has been reported to be closely associated with longevity. Expand
Changes in renin-angiotensin-aldosterone axis in later life. Drug Aging
  • Changes in renin-angiotensin-aldosterone axis in later life. Drug Aging
  • 1994